ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Allen Discusses CO-1686 as a Treatment for Lung Cancer

Andrew R. Allen, BM, BCh, MA, MRCP, PhD
Published: Wednesday, Aug 13, 2014

Andrew R. Allen, BM, BCh, MA, MRCP, PhD, Executive Vice President of Clinical and Pre-Clinical Development, Chief Medical Officer, Co-Founder, Clovis Oncology, provides an overview of CO-1686.

Over the past 10 years, oncologists have been able to use first-generation EGFR inhibitors to treat patients with EGFR-positive lung cancer. However, patients will eventually develop acquired resistance to these agents through a second mutation in EGFR known as T790M

Allen says Clovis has developed CO-1686 to inhibit T790M as well as the activating mutations in EGFR while sparing the inhibition of the normal, or wild-type, EGFR. 

Data for CO-1686 were first presented at ASCO in 2013 with a follow-up this year. Prior to the 2014 ASCO Annual Meeting, CO-1686 was granted a breakthrough therapy designation from the FDA. 

Allen says data on CO-1686 presented at the 2014 ASCO Annual meeting showed that patients with confirmed T790M mutations saw a 60% objective response rate when treated with CO-1686 alone. The median progression-free survival has not yet been reached, Allen says, but the current estimate exceeds 12 months. 
Andrew R. Allen, BM, BCh, MA, MRCP, PhD, Executive Vice President of Clinical and Pre-Clinical Development, Chief Medical Officer, Co-Founder, Clovis Oncology, provides an overview of CO-1686.

Over the past 10 years, oncologists have been able to use first-generation EGFR inhibitors to treat patients with EGFR-positive lung cancer. However, patients will eventually develop acquired resistance to these agents through a second mutation in EGFR known as T790M

Allen says Clovis has developed CO-1686 to inhibit T790M as well as the activating mutations in EGFR while sparing the inhibition of the normal, or wild-type, EGFR. 

Data for CO-1686 were first presented at ASCO in 2013 with a follow-up this year. Prior to the 2014 ASCO Annual Meeting, CO-1686 was granted a breakthrough therapy designation from the FDA. 

Allen says data on CO-1686 presented at the 2014 ASCO Annual meeting showed that patients with confirmed T790M mutations saw a 60% objective response rate when treated with CO-1686 alone. The median progression-free survival has not yet been reached, Allen says, but the current estimate exceeds 12 months. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x